Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

EDDING 亿腾

EDDING GENOR GROUP HOLDINGS LIMITED
亿腾嘉和醫藥集團有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 6998)

PROFIT WARNING

This announcement is made by Edding Genor Group Holdings Limited (the "**Company**", together with its subsidiaries, the "**Group**" or "**our**") pursuant to Rule 13.09(2)(a) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the "**Listing Rules**") and the Inside Information Provisions (as defined under the Listing Rules) of Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

The board (the "**Board**") of directors (the "**Directors**") of the Company wishes to inform the shareholders of the Company (the "**Shareholders**") and potential investors that, based on a preliminary review of the unaudited consolidated management accounts of the Group for the six months ended 30 June 2026 and an assessment of the latest information currently available to the Board, the Group is expected to record (i) revenue of approximately RMB850 million to RMB900 million for the six months ended 30 June 2026 as compared to revenue of approximately RMB1,135.5 million for the six months ended 30 June 2025; and (ii) a net loss of approximately RMB60 million to RMB70 million for the six months ended 30 June 2026, as compared to a net profit of approximately RMB114.6 million for the six months ended 30 June 2025.

The shift from net profit to net loss was primarily attributable to:

i) The inclusion of vancomycin injection in the scope of the Twelfth Batch of the National Centralised Volume-based Drug Procurement in mid-2026. Although the procurement will not take effect until the second half of 2026, the market's anticipatory response has already adversely affected the Group's sales during the Reporting Period, with the impact reflected ahead of schedule.

   Such impact has been mitigated by the growth of the Group's innovative drugs, including Vascepa and Rujianing. The gross sales revenue from the Group's innovative drugs is expected to increase by approximately 50% for the six months ended 30 June 2026 as compared to the same period in 2025. Leveraging the continuous improvement and strategic layout of the Group's commercialized products in recent years, together with its academic promotion, the Group has efficiently consolidated the market foundation for products with core competitive barriers, which is expected to lay a solid foundation and provide strong momentum for the sustained growth of the Group's medium-to-long-term operating performance; and

ii) The continued increases in research and development investment for our product pipeline, resulting in an increase in research and development expenses.

Innovation is the Group's strategic priority following completion of the strategic Merger. The Group will continue to allocate resources to research and development, with a focus on advancing its integrated large-molecule antibody development platforms and small nucleic acid drug development platforms across multiple molecular formats. By accelerating clinical development and commercialisation across high-growth therapeutic areas including breast cancer treatment, large-molecule antibody therapeutics and chronic cardiovascular and metabolic diseases and leveraging the global collaboration value of its pipeline as initially validated by the GB261 transaction bringing proceeds of US$48,419,599.63 in cash in July 2026, the Group anticipates that it will strengthen its market position in innovative differentiated therapeutics and create sustainable long-term value for its shareholders.

As the Company is still in the process of finalizing the results of the Group for the six months ended 30 June 2026, the information contained in this announcement is only based on the Company's preliminary assessment of the unaudited consolidated management accounts and relevant revenue and expenses estimates made available to the Board as of the date of this announcement, which has not been reviewed by the Company's auditors nor by the audit committee of the Board, and the above information may be subject to adjustments. Further details of the Group's financial information will be disclosed in the Group's interim results announcement for the six months ended 30 June 2026, which is expected to be published at the end of August 2026 according to the Listing Rules. As such, the above figures are provided for the Shareholders' and investors' reference only. Shareholders and potential investors are advised to read carefully the interim results announcement of the Company for the six months ended 30 June 2026.

Shareholders and potential investors are advised to exercise due care when dealing in the shares of the Company.

By order of the Board
Edding Genor Group Holdings Limited
Mr. Ni Xin
Chairman and Executive Director

Hong Kong, 21 August 2026

As at the date of this announcement, the Board comprises Mr. Ni Xin and Dr. Han Shuhua as executive Directors; Dr. David Guowei Wang and Mr. Yu Tieming as non-executive Directors; and Dr. Xu Qing, Mr. Chen Wen and Ms. Zheng Jingjing as independent non-executive Directors.